Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | TNKS | O95271 | 4/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20544572 | 0.84 | MAPT (0.40) | ADORA2A | |
| SCHEMBL20544575 | 0.83 | SSTR4 (0.36) | ARTNKSTNKS2PARP1 | |
| SCHEMBL21026893 | 0.76 | GPR84 (0.39) | — | |
| SCHEMBL20544987 | 0.76 | KEAP1 (0.44) | KEAP1NFE2L2HTR1AADRA1DADRA1A | |
| SCHEMBL20189141 | 0.68 | IDO1 (0.44) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14881515 | 0.68 | HTR2A (0.35) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31726732 | 0.67 | KEAP1 (0.47) | KEAP1NFE2L2HTR1AADRA1DADRA1A | |
| SCHEMBL19860981 | 0.67 | BACE1 (0.39) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL20544567 | 0.66 | AKR1B1 (0.34) | ADORA2A | |
| SCHEMBL4681216 | 0.66 | IDO1 (0.40) | KDM4EALDH1A1HPGDHSD17B10ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831942-B | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3998269-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3615533-B1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| EP-3615533-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| CN-110831942-A | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20180312507-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-11-01 | — | — | US | disclosed |
| WO-2018198079-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885HTR1A 2956/4885 |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885HTR1A 2956/4885 |
| US-20180312507-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885HTR1A 2956/4885 |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885HTR1A 2956/4885 |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885HTR1A 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.